Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Positive Results from Ph 3 TALENTACE Study of Tecentriq and Avastin for Unresectable HCC announced

May 27, 2025

Trodelvy Demonstrates Significant PFS Improvement in 1L Metastatic TNBC Patients Not Candidates for Checkpoint Inhibitors in ASCENT-03 trial

May 27, 2025

First Follicular Lymphoma Patient Treated with PMB-CT01 Achieves a Complete Response

May 27, 2025

New Two-Year Follow-Up of Columvi Extends OS in R/R DLBCL Patients

May 27, 2025

New Positive Data Announced for iMMagine-1 Study in Patients with R/R Multiple Myeloma

May 21, 2025

FAILED TRIAL: GALAXIES Lung-201 of Belrestotug + Dostarlimab in 1L PD-L1 High NSCLC Patients did not meet PFS endpoint

May 21, 2025

Positive final results in Ph 1 ACTIVATE trial in liver mets from CRC announced

May 21, 2025

Ten-year APHINITY data show Perjeta-based regimen reduced the risk of death by 17% in people with HER2+ve early-stage breast cancer

May 21, 2025

Ph 3 Trial of Disitamab Vedotin in 1L HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma meets Primary Endpoints of PFS and OS

May 21, 2025

Ph 3 KEYNOTE-B96 Trial Met Primary PFS Endpoint in Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers

May 21, 2025

Updated Ph 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the treatment of NHL Announced

May 21, 2025

Two Ph 2 trials of Samuraciclib + SERDs in HR+ve Advanced Breast Cancer demonstrate extended PFS in patients without TP53 mutations or without liver mets

May 21, 2025

Enhertu followed by THP before surgery showed statistically significant pCR improvement high-risk HER2-positive early-stage breast cancer patients in DESTINY-Breast11 Ph 3 trial

May 13, 2025

Statistically Significant Topline Results from Global Ph 2 Trial of Elraglusib in 1L Treatment of Metastatic Pancreatic Cancer Announced

May 13, 2025

Pivotal Revumenib Data in R/R mNPM1 AML published in the Journal Blood

May 13, 2025

Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Ph 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in 1L Metastatic Pancreatic Cancer Patients

May 13, 2025

Imfinzi regimen demonstrated statistically significant DFS improvement in high-risk NMIBC in POTOMAC Ph 3 trial

May 13, 2025

Preliminary Clinical Data for CT0596 Announced, Demonstrating Favorable Safety and Efficacy

May 13, 2025

Elironrasib monotherapy demonstrated acceptable tolerability and encouraging initial antitumor activity in previously treated G12C NSCLC patients

May 13, 2025

Ph 2/3 trial of 2L+ KN026 + chemo in HER2-positive gastric/GEJ cancer met the primary endpoint of PFS at interim analysis

May 6, 2025

Efti + KEYTRUDA Combo Drives Strong OS in Head and Neck Cancer with CPS <1

May 6, 2025

Full Results Announced From Completed Ph 1 Study of JNJ-1900 (NBTXR3) in Pancreatic Cancer

May 6, 2025

CR achieved after 1 month of the in vivo CD19 CAR-T treatment, with durable response sustained over three months in R/R DLBCL patients

May 6, 2025

Higher Exposure of AFM24 Associated with Significantly Higher Response Rates and PFS in Refractory NSCLC Patients

May 6, 2025

Tuspetinib-based Triplet regimen in 1L AML Patients in Ph 1/2 TUSCANY Trial Demonstrates Safety, Complete Remissions

May 6, 2025
Page1 Page2 Page3 … Page30

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.